Navigation Links
Biotest Pharmaceuticals Corporation Announces Management Team
Date:12/4/2007

revention of hepatitis C in liver transplant patients. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 500 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 1,750 people worldwide.

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops and markets immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or hematopoietic system. In the Biotherapeutic segment, Biotest researches in the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are predominantly used in hygiene control, as well as serology, used, for example, in blood transfusions. Biotest has around 1,750 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard.


'/>"/>
SOURCE Biotest Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
2. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Charm Sciences, Inc. is pleased ... (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... Sciences to monitor aflatoxin in grains utilizing Charm’s ... FAST Aflatoxin Quantitative Test (solvent-based). , The Charm ... Water Extraction Technology to extract aflatoxin from the ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... , , ATLANTA, Sept. ... Board: EAUI), a leading provider of electrolyzed water for high-volume, ... trial with a leading international beverage bottling company enabling the ... sanitation process for CIP (Clean-in-Place) applications. EAU,s electrolyzed water ...
... , ... Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities. ... Basel, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, ...
... , , , CLEVELAND, ... GanedenBC30(R) , today announced the launch of the first ... the latest in a number of innovative probiotic-enhanced products introduced by Ganeden ... recent popularity of thin strips as a supplement delivery system led Ganeden ...
Cached Biology Technology:EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant mouse ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
E1A (adenovirus early region 1)...
Biology Products: